ANTX AN2 Therapeutics, Inc.

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

As of 06/28/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  03/25/2022
Outstanding shares:  19,402,658
Average volume:  100,905
Market cap:   $169,773,258
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.05
PB ratio:   1.47
PS ratio:   0.00
Return on equity:   2,844.16%
Net income %:   4.85%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy